The FDA is evaluating and investigating reports of possible rare side effects linked with the diabetes and weight loss drugs including Ozempic, Wegovy and Mounjaro.
People taking the drugs are reporting symptoms of hair loss, breathing problems, and suicidal thoughts.
The FDA probe means that the “FDA has identified a potential safety issue, but it does not mean that FDA has identified a causal relationship between the drug and the listed risk.”
The FDA reports it is evaluating the need for regulatory actions and once the investigation is complete, they could possibly update the drug labels with any new information, and/or put together a risk management plan into place to manage or prevent health risks.
It is possible they may find nothing and no changes may not need occur. It is unclear how long the evaluation and investigation will take.
By - FZ
Comments